HRMY NASDAQ
Harmony Biosciences Holdings, Inc.
1W: -0.9%
1M: -4.6%
3M: +4.6%
YTD: -18.4%
1Y: -14.4%
3Y: -15.1%
5Y: +9.4%
$30.15
-0.34 (-1.12%)
Weekly Expected Move ±6.2%
$26
$28
$30
$32
$34
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (68)
A beaten-down biotech just lost a meaningful backer — should you care?
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
Is Harmony Biosciences Holdings, Inc. (HRMY) One of The Best Small Cap Value Stocks to Buy?
Harmony outlines $1B-$1.04B 2026 net revenue plan while targeting pitolisant GR PDUFA in Q1 2027
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Harmony Biosciences Holdings, Inc. GAAP EPS of $0.55 misses by $0.14, revenue of $215.3M misses by $5.54M
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet
Should Value Investors Buy CSL Limited (CSLLY) Stock?
Cwm LLC Purchases 18,449 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Q3 Earnings Estimate for HRMY Issued By HC Wainwright
What is HC Wainwright’s Estimate for HRMY Q1 Earnings?
12 Health Care Stocks Moving In Tuesday's After-Market Session
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of “Hold” by Brokerages
Peter Anastasiou At Harmony Biosciences Hldgs Exercises Options Worth $0
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Recommendation of “Hold” from Brokerages
Are Options Traders Betting on a Big Move in Harmony Biosciences Stock?
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest Up 47.0% in February
Harmony Biosciences Holdings, Inc. $HRMY Shares Acquired by American Century Companies Inc.
HC Wainwright Issues Pessimistic Forecast for HRMY Earnings
Harmony Biosciences targets $1B–$1.04B WAKIX revenue in 2026 while expanding late-stage CNS pipeline
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. Non-GAAP EPS of $0.57 misses by $0.50, revenue of $243.78M beats by $3.46M
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Here are the major earnings before the open Tuesday
Harmony Biosciences tumbles following Deutsche Bank, Truist downgrades
Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Preview
Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY)
Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade
HRMY vs. ARGX: Which Stock Is the Better Value Option?
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
New York State Common Retirement Fund Acquires 29,501 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity
Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800
Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800
Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes"
How Harmony Biosciences Can Prove Its Skeptics Wrong
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
I Was Shocked to Find This Value-Priced Biotech Growth Stock
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Campbell & CO Investment Adviser LLC Has $796,000 Holdings in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
CX Institutional Has $6.35 Million Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Jeffrey Dayno Sells 25,933 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock
Harmony Biosciences (NASDAQ:HRMY) Shares Down 3.9% Following Insider Selling
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
Federated Hermes Inc. Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Boston Partners Takes $19.40 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by American Century Companies Inc.
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Envestnet Asset Management Inc. Sells 15,944 Shares of Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence